Highlights

  • Anteris Technologies shares closed at AUD 9.69, up 32.92% on 21 January 2026 after the public offering announcement.
  • The company announced a USD  200 million underwritten public offering of common stock and a 30-day option for an additional USD  30 million of shares.
  • Medtronic will participate in a private placement of up to USD  90 million at the same price as the public offering to acquire 16–19.99% of outstanding shares post-offering.

Shares of Anteris Technologies Global Corp. (ASX:AVR) surged 32.92% to AUD 9.69 on 21 January 2026, following the announcement of a proposed USD 200 million public offering and a strategic private placement with Medtronic. The capital raising is intended to support clinical trials, expand manufacturing, and fund research and development for the company’s lead structural heart technology, DurAVR® Transcatheter Heart Valve (DurAVR® THV).

Public Offering to Support Growth and Trials

Anteris Technologies launched a USD  200 million public offering to fund its next stage of growth and the global pivotal trial of its DurAVR® THV for severe aortic stenosis, known as the PARADIGM Trial. The offering is underwritten and includes a 30-day option for underwriters to purchase an additional USD  30 million in shares.

The net proceeds, along with existing cash and the private placement proceeds, will support the company’s clinical execution, expand manufacturing capabilities, and fund ongoing research and development through its subsidiary, v2vmedtech, Inc. Remaining funds will be allocated to working capital and other corporate purposes.

Strategic Medtronic Investment

As part of a stock purchase agreement, Anteris will sell up to USD  90 million of shares to Medtronic, subject to a minimum of 16% and a maximum of 19.99% of post-offering outstanding shares. The private placement is contingent on the completion of the public offering. Medtronic’s participation is aimed at providing strategic investment support and reinforcing confidence in Anteris’ technology pipeline.

Barclays, Wells Fargo Securities, and Cantor Fitzgerald are acting as joint book-running managers for the public offering. Barrenjoey Markets Pty Limited serves as the financial advisor for Asia-Pacific investors, and Wells Fargo Securities is handling the Medtronic private placement.

About Anteris Technologies

Founded in Australia, Anteris Technologies is a structural heart company developing medical devices to restore heart function. Its lead product, the DurAVR® THV, is a balloon-expandable, biomimetic aortic valve designed to mimic the performance of a healthy human valve. The valve is made from Anteris’ FDA-cleared ADAPT® tissue, which has been used in over 55,000 patients worldwide.